Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit : 90-Day Results from the INSPIRATION Randomized Trial
Thieme. All rights reserved..
BACKGROUND: Thrombotic complications are considered among the main extrapulmonary manifestations of coronavirus disease 2019 (COVID-19). The optimal type and duration of prophylactic antithrombotic therapy in these patients remain unknown.
METHODS: This article reports the final (90-day) results of the Intermediate versus Standard-dose Prophylactic anticoagulation In cRitically-ill pATIents with COVID-19: An opeN label randomized controlled trial (INSPIRATION) study. Patients with COVID-19 admitted to intensive care were randomized to intermediate-dose versus standard-dose prophylactic anticoagulation for 30 days, irrespective of hospital discharge status. The primary efficacy outcome was a composite of adjudicated venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation (ECMO), or all-cause death. The main safety outcome was major bleeding.
RESULTS: Of 600 randomized patients, 562 entered the modified intention-to-treat analysis (median age [Q1, Q3]: 62 [50, 71] years; 237 [42.2%] women), of whom 336 (59.8%) survived to hospital discharge. The primary outcome occurred in 132 (47.8%) of patients assigned to intermediate dose and 130 (45.4%) patients assigned to standard-dose prophylactic anticoagulation (hazard ratio [HR]: 1.21, 95% confidence interval [CI]: 0.95-1.55, p = 0.11). Findings were similar for other efficacy outcomes, and in the landmark analysis from days 31 to 90 (HR: 1.59, 95% CI: 0.45-5.06). There were 7 (2.5%) major bleeding events in the intermediate-dose group (including 3 fatal events) and 4 (1.4%) major bleeding events in the standard-dose group (none fatal) (HR: 1.82, 95% CI: 0.53-6.24).
CONCLUSION: Intermediate-dose compared with standard-dose prophylactic anticoagulation did not reduce a composite of death, treatment with ECMO, or venous or arterial thrombosis at 90-day follow-up.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:122 |
|---|---|
| Enthalten in: |
Thrombosis and haemostasis - 122(2022), 1 vom: 01. Jan., Seite 131-141 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 20.01.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/a-1485-2372 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324199228 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324199228 | ||
| 003 | DE-627 | ||
| 005 | 20231225185815.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/a-1485-2372 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1080.xml |
| 035 | |a (DE-627)NLM324199228 | ||
| 035 | |a (NLM)33865239 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bikdeli, Behnood |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit |b 90-Day Results from the INSPIRATION Randomized Trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.01.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a BACKGROUND: Thrombotic complications are considered among the main extrapulmonary manifestations of coronavirus disease 2019 (COVID-19). The optimal type and duration of prophylactic antithrombotic therapy in these patients remain unknown | ||
| 520 | |a METHODS: This article reports the final (90-day) results of the Intermediate versus Standard-dose Prophylactic anticoagulation In cRitically-ill pATIents with COVID-19: An opeN label randomized controlled trial (INSPIRATION) study. Patients with COVID-19 admitted to intensive care were randomized to intermediate-dose versus standard-dose prophylactic anticoagulation for 30 days, irrespective of hospital discharge status. The primary efficacy outcome was a composite of adjudicated venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation (ECMO), or all-cause death. The main safety outcome was major bleeding | ||
| 520 | |a RESULTS: Of 600 randomized patients, 562 entered the modified intention-to-treat analysis (median age [Q1, Q3]: 62 [50, 71] years; 237 [42.2%] women), of whom 336 (59.8%) survived to hospital discharge. The primary outcome occurred in 132 (47.8%) of patients assigned to intermediate dose and 130 (45.4%) patients assigned to standard-dose prophylactic anticoagulation (hazard ratio [HR]: 1.21, 95% confidence interval [CI]: 0.95-1.55, p = 0.11). Findings were similar for other efficacy outcomes, and in the landmark analysis from days 31 to 90 (HR: 1.59, 95% CI: 0.45-5.06). There were 7 (2.5%) major bleeding events in the intermediate-dose group (including 3 fatal events) and 4 (1.4%) major bleeding events in the standard-dose group (none fatal) (HR: 1.82, 95% CI: 0.53-6.24) | ||
| 520 | |a CONCLUSION: Intermediate-dose compared with standard-dose prophylactic anticoagulation did not reduce a composite of death, treatment with ECMO, or venous or arterial thrombosis at 90-day follow-up | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Enoxaparin |2 NLM | |
| 700 | 1 | |a Talasaz, Azita H |e verfasserin |4 aut | |
| 700 | 1 | |a Rashidi, Farid |e verfasserin |4 aut | |
| 700 | 1 | |a Bakhshandeh, Hooman |e verfasserin |4 aut | |
| 700 | 1 | |a Rafiee, Farnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaeifar, Parisa |e verfasserin |4 aut | |
| 700 | 1 | |a Baghizadeh, Elahe |e verfasserin |4 aut | |
| 700 | 1 | |a Matin, Samira |e verfasserin |4 aut | |
| 700 | 1 | |a Jamalkhani, Sepehr |e verfasserin |4 aut | |
| 700 | 1 | |a Tahamtan, Ouria |e verfasserin |4 aut | |
| 700 | 1 | |a Sharif-Kashani, Babak |e verfasserin |4 aut | |
| 700 | 1 | |a Beigmohammadi, Mohammad Taghi |e verfasserin |4 aut | |
| 700 | 1 | |a Farrokhpour, Mohsen |e verfasserin |4 aut | |
| 700 | 1 | |a Sezavar, Seyed Hashem |e verfasserin |4 aut | |
| 700 | 1 | |a Payandemehr, Pooya |e verfasserin |4 aut | |
| 700 | 1 | |a Dabbagh, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Moghadam, Keivan Gohari |e verfasserin |4 aut | |
| 700 | 1 | |a Khalili, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Yadollahzadeh, Mahdi |e verfasserin |4 aut | |
| 700 | 1 | |a Riahi, Taghi |e verfasserin |4 aut | |
| 700 | 1 | |a Abedini, Atefeh |e verfasserin |4 aut | |
| 700 | 1 | |a Lookzadeh, Somayeh |e verfasserin |4 aut | |
| 700 | 1 | |a Rahmani, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Zoghi, Elnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammadi, Keyhan |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghipour, Pardis |e verfasserin |4 aut | |
| 700 | 1 | |a Abri, Homa |e verfasserin |4 aut | |
| 700 | 1 | |a Tabrizi, Sanaz |e verfasserin |4 aut | |
| 700 | 1 | |a Mousavian, Seyed Masoud |e verfasserin |4 aut | |
| 700 | 1 | |a Shahmirzaei, Shaghayegh |e verfasserin |4 aut | |
| 700 | 1 | |a Amin, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Mohebbi, Bahram |e verfasserin |4 aut | |
| 700 | 1 | |a Parhizgar, Seyed Ehsan |e verfasserin |4 aut | |
| 700 | 1 | |a Aliannejad, Rasoul |e verfasserin |4 aut | |
| 700 | 1 | |a Eslami, Vahid |e verfasserin |4 aut | |
| 700 | 1 | |a Kashefizadeh, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Dobesh, Paul P |e verfasserin |4 aut | |
| 700 | 1 | |a Kakavand, Hessam |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseini, Seyed Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Shafaghi, Shadi |e verfasserin |4 aut | |
| 700 | 1 | |a Ghazi, Samrand Fattah |e verfasserin |4 aut | |
| 700 | 1 | |a Najafi, Atabak |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez, David |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Aakriti |e verfasserin |4 aut | |
| 700 | 1 | |a Madhavan, Mahesh V |e verfasserin |4 aut | |
| 700 | 1 | |a Sethi, Sanjum S |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Sahil A |e verfasserin |4 aut | |
| 700 | 1 | |a Monreal, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Hadavand, Naser |e verfasserin |4 aut | |
| 700 | 1 | |a Hajighasemi, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Maleki, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghian, Saeed |e verfasserin |4 aut | |
| 700 | 1 | |a Piazza, Gregory |e verfasserin |4 aut | |
| 700 | 1 | |a Kirtane, Ajay J |e verfasserin |4 aut | |
| 700 | 1 | |a Van Tassell, Benjamin W |e verfasserin |4 aut | |
| 700 | 1 | |a Stone, Gregg W |e verfasserin |4 aut | |
| 700 | 1 | |a Lip, Gregory Y H |e verfasserin |4 aut | |
| 700 | 1 | |a Krumholz, Harlan M |e verfasserin |4 aut | |
| 700 | 1 | |a Goldhaber, Samuel Z |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghipour, Parham |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thrombosis and haemostasis |d 1979 |g 122(2022), 1 vom: 01. Jan., Seite 131-141 |w (DE-627)NLM000103896 |x 2567-689X |7 nnns |
| 773 | 1 | 8 | |g volume:122 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:131-141 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-1485-2372 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 122 |j 2022 |e 1 |b 01 |c 01 |h 131-141 | ||